70 results
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
Prospectus, including timely filing with the Commission or retention where required and legending; and
(c) The Company agrees that if at any time
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
manufacturing costs were incurred and expensed to research and development expense, and the employee retention credit;
S-6
our ability to successfully
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
lines, for which the related manufacturing costs were incurred and expensed to research and development expense, and the employee retention credit;
S
8-K
EX-10.2
66nx5g0pbmrgb2p221
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-99.1
mvqi a0z5t3adv
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-1.1
ny0fz4ce15hix 8csxxd
13 Sep 22
Other Events
9:55pm